CLINICAL INTERVENTIONS IN AGING, cilt.11, ss.1193-1198, 2016 (SCI-Expanded)
Background: Second-generation antipsychotics (SGAs) have been used in the augmentation of treatment-resistant depression. However, little is known about their effectiveness, tolerability, and adverse events in the treatment of late-life depression, which were the aim of this study.